Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The presentations cover topics including: Update from TGA to Sector (A01c) Manufacturing Quality and GMP Clearance (A02) In vitro diagnostic (IVD) medical device - reforms and processes (A05) Finding the way to the ARTG for medical devices (A11) Section 19A vs Section 14/14A: a practical approach to reducing the impact of medicine shortages (A16) Software and AI compliance and reforms (A17) Clinical Trials and Good Clinical Practice (GCP) (B02) Labelling TGO 92 update - non-prescription medicines (B09) Labelling TGO 91 update - prescription medicines (B22) Update from TGAs Pharmacovigilance Branch (B13) Prescription Medicine Authorisation Branch update - Q&A panel session (B16) Real World Evidence (C08) A sincere thank you to the TGA presenters for sharing their expertise at the conference and for making these resources available to the wider community
The true cost of a low-quality peptide isn't its sticker price
Building and maintaining a rigorously-vetted catalog backed by our uncompromising standards
Myth 1: GLP-1 Medications Are Only for Diabetics Reality Check: While its true that semaglutide and tirzepatide were initially developed for diabetes management, their benefits extend far beyond controlling blood sugar
Rehman SU, Ali R, Zhang H, Zafar MH, Wang M
PMCID: PMC539316
US$ 28.93
US$ 26.80
US$ 24.83
US$ 24.86
US$ 22.07
US$ 23.97
